Treatment of anxiety disorders in adolescents

Not Applicable

Completed

• Conditions: Adolescent anxiety disorders; Mental and Behavioural Disorders; Anxiety disorder, unspecified

• Registration Number: ISRCTN86123204
• Lead Sponsor: niversity of Reading

Brief Summary

2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/31023352 protocol (added 29/04/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-11-23
• Study Completion: 2019-06-04
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

1. Young people (aged 11-17.5 years at intake) whose primary presenting disorder is a DSM-5 diagnosis of an anxiety disorder
2. If young people have been prescribed psychotropic medication the dosage must have been stable for two months

Exclusion Criteria

1. Young people with co-morbid conditions that are likely to interfere with treatment delivery, to include an established autistic spectrum disorder or learning disabilities, suicidal intent or recurrent or potentially life-limiting self-harm (i.e., current frequency of at least once per week or self-harm that requires medical attention)
2. Young people with a primary presenting disorder other than an anxiety disorder (including a DSM-V diagnosis of major depressive disorder (MDD))
3. Young people identified by social services as currently ‘at risk’ due to child protection concerns

Study & Design

• Study Type: Interventional
• Study Design: Not specified